Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ofatumumab in Pemphigus Vulgaris
NCT01920477Phase 3Terminated
- Sponsor
- Novartis
- Start
- Aug 2013
- Primary completion
- Apr 2016
- Modality
- Monoclonal Antibodies
- Countries
- 8
01
Overview
A Phase 3 trial of ofatumumab in pemphigus vulgaris (PV), sponsored by Novartis. Started Aug 2013; status: terminated.
02
Drugs
ofatumumab
03
Conditions
pemphigus vulgaris (PV)
Beyond the preview
Go deeper on NCT01920477.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01920477.